ArticleScientific reports2025
Silver nanoparticles derived from Streptomyces sp. YJD18 with multifunctional biomedical applications.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
A sustainable and energy-efficient approach was developed for the biosynthesis of silver nanoparticles (AgNPs) using a cell-free supernatant derived from Streptomyces sp. strain YJD18, an actinomycete isolated from saline soil. Optimized synthesis conditions, including pH 10 and a biomass concentration of 5 g/100 mL, facilitated the rapid formation of AgNPs. The highest yield was achieved by mixing the supernatant with silver nitrate (AgNO₃) at a 4:1 ratio, followed by incubation at 100 °C for 15 min.The synthesized AgNPs exhibited multifunctional bioactivities, including antibacterial, anticancer, antioxidant, and wound-healing properties, as confirmed by UV-Vis spectroscopy, transmission electron microscopy (TEM), X-ray diffraction (XRD), dynamic light scattering (DLS), high-angle annular dark field-scanning transmission electron microscopy (HAADF-STEM), Fourier-transform infrared spectroscopy (FTIR), and energy-dispersive X-ray spectroscopy (EDX). The formation of AgNPs was indicated by a characteristic color change, with UV-Vis spectral analysis revealing a distinct absorption peak at 420 nm. Morphological analysis showed that the nanoparticles were predominantly spherical, with a few triangular and cylindrical structures, measuring 50-80 nm in size, with a polydispersity index (PDI) of 0.312 and a zeta potential of -24.0 mV, indicating moderate colloidal stability. The AgNPs exhibited potent antibacterial activity against both Gram-positive (G⁺) and Gram-negative (G⁻) bacteria, with synergistic effects observed in combination with standard antibiotics. Furthermore, the AgNPs displayed significant anticancer activity, with pronounced cytotoxic effects against human pulmonary carcinoma (A549) and human liver hepatocellular carcinoma (HepG2) cell lines, compared to their effects on human breast adenocarcinoma (MDA-MB-231) and human cervical carcinoma (HeLa) cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.